Overview

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2025-06-18

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Palbociclib